Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

Maria Napolitano,1,* Ferdinando D’Amico,1,2,* Elisa Ragaini,2,* Laurent Peyrin-Biroulet,3,4 Silvio Danese1 1Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy; 2Department of Biomedical Sciences, Humanitas Univers...

Full description

Bibliographic Details
Main Authors: Napolitano M, D'Amico F, Ragaini E, Peyrin-Biroulet L, Danese S
Format: Article
Language:English
Published: Dove Medical Press 2022-06-01
Series:Drug Design, Development and Therapy
Subjects:
upadacitinib
small molecule
jak1 inhibitor
ulcerative colitis
inflammatory bowel disease
Online Access:https://www.dovepress.com/evaluating-upadacitinib-in-the-treatment-of-moderate-to-severe-active--peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/evaluating-upadacitinib-in-the-treatment-of-moderate-to-severe-active--peer-reviewed-fulltext-article-DDDT

Similar Items